• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22263 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (atopic dermatitis) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Upadacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Unrelated donor stem cell transplantation acquired severe aplastic anaemia]
2010     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Unrelated donor allogeneic stem cell transplantation for Hodgkin's lymphoma]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Unplanned hospital readmissions in Catalonia]
2007     Andalusian Health Technology Assessment Area (AETSA) [Universal leukorreduction. A systematic review of the literature and an economic assessment]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Uncertainty in the efficiency frontiers]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Umeclidinium/vilanterol - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Umeclidinium - Benefit assessment according to §35a Social Code Book V]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Umbilical artery Doppler ultrasonography in high risk pregnancies]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for uterine fibroids: Assessment according to §137h Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for uterine fibroids - Addendum to commission H16-02B]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for uterine fibroids - 2nd addendum to commission H16-02B]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for secondary malignant neoplasms of the liver and the intrahepatic bile ducts - Assessment according to §137h Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for secondary malignant neoplasms of the liver and the intrahepatic bile ducts - Addendum to commission H16-02E]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for secondary malignant neoplasms of the bone - Assessment according to §137h Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas not treatable by surgery - 3rd addendum to commission H16-02C]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas - second Addendum to Commission H16-02C]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas - Assessment according to §137h Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the pancreas - Addendum to commission H16-02C]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the liver and the intrahepatic bile ducts - Assessment according to §137h Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the liver and the intrahepatic bile ducts - 2nd addendum to commission H16-02D]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the liver and intrahepatic bile ducts - Addendum to commission H16-02D]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for malignant neoplasms of the bone and the joint cartilage: Assessment according to §137h Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound-guided high-intensity focused ultrasound for endometriosis of the uterus: Assessment according to §137h Social Code Book V]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Ultrasound therapy for scar tissue]
2008     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound screening in pregnancy - test quality with regard to the detection rates of foetal abnormalities]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ultrasound screening for abdominal aortic aneurysms]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Ultrasound imaging in the diagnosis of carpal tunnel syndrome]
2014     Haute Autorite de sante (HAS) [Ultrasound guidance for peripheral nerve blockade]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Ultrasensitive C-reactive protein as a prognostic biomarker for cardiovascular disease]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Ulipristal in uterine myomatosis]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [UAE and MRgFUS versus myoma enucleation - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Type 2 diabetes. Health technology assessment of screening, diagnosis and treatment - systematic review]
2008     The Swedish Council on Health Technology Assessment (SBU) [Tympanostomy tube insertion for otitis media in children]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Turoctocog alfa pegol - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Turoctocog alfa - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tumour-treating fields in addition to current standard therapy for glioblastoma as first-line treatment - Rapid report]
2002     Basque Office for Health Technology Assessment (OSTEBA) [Tumour markers in certain cancer locations]
2013     Andalusian Health Technology Assessment Area (AETSA) [Tumor treating fields therapy (TTF) for glioblastoma. A systematic review of the literature]
2020     Andalusian Health Technology Assessment Area (AETSA) [Tumor field therapy in the treatment of glioblastoma. Update]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tucatinib (breast cancer) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tucatinib (breast cancer) - Addendum to Commission A21-26]
2012     Haute Autorite de sante (HAS) [Tubular orthoses and bandages used in orthopaedics/degenerative rheumatology/traumatology]
2008     Haute Autorite de sante (HAS) [Tubal anastomosis by laparoscopy or laparotomy for sterilization reversal]
2009     Committee for New Health Technology Assessment (CNHTA) [TruScreen - cervical cancer screening system]
2008     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Triptans as treatment for moderate to severe migraine attacks]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Triptan overuse in migraine in primary care, a proactive approach]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Triple-phase computed tomography in patients with liver lesion]
2000     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Triple test for all pregnant women? A health technology assessment]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifluridine/tipiracil (gastric cancer) - Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifluridine/tipiracil (combination with bevacizumab; colorectal cancer) – Addendum to Project A23-85]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifluridine/tipiracil (colorectal cancer): Addendum to Commission A16-54]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifluridine/tipiracil (colorectal cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifluridine/tipiracil (colorectal cancer) - Addendum to Commission A20-35]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Trifarotene (acne vulgaris) - Benefit assessment according to §35a Social Code Book V]
2023     Norwegian Institute of Public Health (NIPH) [Triclosan coated sutures for prevention of surgical site infection: a health technology assessment]
2011     Norwegian Knowledge Centre for the Health Services (NOKC) [Triage systems for emergency medical services – pre-hospital and at hospital admission]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Treprostinil in chronic thromboembolic pulmonary hypertension (group 4)]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab and durvalumab (NSCLC) – Second addendum to Project A23-29 | A23-31]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab and durvalumab (NSCLC) - Addendum to Commissions A23-29 and A23-31]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab and durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab and durvalumab (hepatocellular carcinoma [HCC]) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Tremelimumab (NSCLC) – Benefit assessment according to §35a Social Code Book V]
2013     Andalusian Health Technology Assessment Area (AETSA) [Treatments for localized prostate cancer: Radical prostatectomy versus brachytherapy. Systematic review of the literature and case series]
2022     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatments for extreme nausea and vomiting in pregnancy (hyperemesis gravidarum)]
2013     Andalusian Health Technology Assessment Area (AETSA) [Treatment with biological drugs in adult patients with moderate to severe plaque psoriasis: relative efficacy, safety and efficiency]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment switching in oncological studies]
2017     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) [Treatment options of arm fractures in the elderly]
2017     The Swedish Council on Health Technology Assessment (SBU) [Treatment options of arm fractures in the elderly]
2018     Haute Autorite de sante (HAS) [Treatment of superficial stomach cancer by endoscopic submucosal dissection (ESD)]
2009     Committee for New Health Technology Assessment (CNHTA) [Treatment of sepsis caused by G(-) bacteria through Toraymyxin]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Treatment of recurrent clostridium difficile infection with fecal therapy: the FECAL trial (Fecal enema to Eliminate Clostridium difficile Associated Longstanding diarrhea)]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Treatment of pseudomyxoma peritonei]
2010     Norwegian Knowledge Centre for the Health Services (NOKC) [Treatment of pregnant women with asymptomatic bacterial vaginosis with clindamycin]
2000     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Treatment of pneumonia with penicillins: oral or intravenous?]
2002     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Treatment of patients with energy]
2010     Norwegian Knowledge Centre for the Health Services (NOKC) [Treatment of patients with acute stroke in stroke units (with or without early supported discharge)]
2001     Finnish Office for Health Care Technology Assessment (Finohta) [Treatment of pain caused by endometriosis]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment of obesity in patients with diabetes mellitus type 2 - Guideline synopsis and additional search for and assessment of systematic reviews]
2012     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Treatment of obesity in children and adolescents in primary and secondary care settings recommendations: clinical practice guidelines]
2010     Haute Autorite de sante (HAS) [Treatment of multiple missing teeth in adults with rare diseases by using implant-supported denture]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Treatment of medication-resistant hallucinations with repetitive transcranial magnetic stimulation (rTMS)]
2016     The Swedish Council on Health Technology Assessment (SBU) [Treatment of maternal birth injuries following vaginal birth – mapping of systematic reviews]
2010     Committee for New Health Technology Assessment (CNHTA) [Treatment of lagophthalmos with gold weight implantation]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Treatment of haemophilia patients - Rapid report]
2000     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Treatment of gallstone patients]
2011     Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment of esophageal cancer: systematic review on surgical techniques]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Treatment of early-stage breast cancer by conservative surgery and intracavitary balloon brachytherapy]
2009     The Regional Health Technology Assessment Centre (HTA-centrum) [Treatment of early rheumatoid arthritis with a combination of TNF-alpha inhibitors and methotrexate, versus methotrexate alone]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Treatment of depression]
2011     Norwegian Knowledge Centre for the Health Services (NOKC) [Treatment of chronic fatigue syndrome CFS/ME]
2011     Institut national d'excellence en sante et en services sociaux (INESSS) [Treatment of cancer-related secondary lymphedema]
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Treatment of benign thyroid by thermal laser or radiofrequency ablation]
2011     Institute for Clinical Effectiveness and Health Policy (IECS) [Treatment of benign prostatic hypertrophy - Barreiro method]
2012     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Treatment of aortic stenosis with the sutureless ATS 3f Enable bioprothesis]
2006     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Treatment of alcohol abuse: a health technology assessment]